

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jenscare Scientific Co., Ltd.
寧波健世科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 9877)

VOLUNTARY ANNOUNCEMENT

**RELEASE OF THE RESULTS OF
THE MULTICENTER CLINICAL TRIAL OF
LUX-VALVE PLUS AT THE 2023 TCT IN THE U.S.**

This announcement is made by Jenscare Scientific Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and new product development of the Group.

The board (“**Board**”) of directors (“**Directors**”) of the Company is pleased to announce that Professor Ge Junbo from Zhongshan Hospital affiliated to Fudan University (復旦大學附屬中山醫院) and his team will give a report on the results of the multicenter clinical trial of LuX-Valve Plus at the 2023 Transcatheter Cardiovascular Therapeutics conference (“**TCT**”) in the U.S. LuX-Valve Plus is the second-generation transjugular vein tricuspid valve replacement system independently developed by the Company.

The 2023 TCT will be held in San Francisco, California, the U.S. from October 23, 2023 to October 26, 2023. The TCT is the annual scientific symposium held by the Cardiovascular Research Foundation (“**CRF**”) and is the largest and most influential global conference focusing on cardiovascular interventional medicine in the world.

We are actively promoting the clinical trials for CE Certificate in Europe, the clinical trials for FDA registration in the U.S. and the fee-for-service compassionate treatment in the Asia-Pacific region of LuX-Valve Plus.

The shareholders of the Company and potential investors can refer to Professor Ge Junbo’s speech at the 2023 TCT to obtain more information about this product and its clinical research.

Cautionary Statement as required by Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that the Company will ultimately develop, market and/or commercialize LuX-Valve Plus successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Jenscare Scientific Co., Ltd.
Mr. LV Shiwen
Chairman and Executive Director

Hong Kong, October 19, 2023

As at the date of this announcement, the executive Directors are Mr. LV Shiwen and Mr. PAN Fei; the non-executive Directors are Mr. TAN Ching, Mr. ZHENG Jiaqi, Ms. XIE Youpei and Mr. CHEN Xinxing; and the independent non-executive Directors are Dr. LIN Shoukang, Ms. DU Jiliu and Dr. MEI Lehe.